Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IP…
FAIL · Does not pass the screen
17.96 USD
At the last full screen 2026-08-27
Screened 2026-08-27 · the tape above runs as of 10:31 UTC · 13 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Trevi Therapeutics, Inc. holds its Markdown at $17.96. The statistical read favours the sellers, held for 159 days.
As held on the ledger · 2026-08-27
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 159 days
Price at the screen
$17.96
Valuation
N/A trailing · -31.13 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.07
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.39%
Below 33%
Interest-bearing debt is just 0.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
87.54%
Below 33%
Interest-bearing cash and securities are 87.5% of assets, above the one-third limit.
Fail
Receivables
9.78%
Below 49%
Money owed to the company is 9.8% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 39.2% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +39% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Chronic Cough Biotech Hits Ethical Data Wall
Picture a firm pouring cash into trials for a cough drug aimed at scarred lungs, yet still years from any revenue. Trevi sits at that exact stage, a clinical biotech with zero profit margin and a return on equity stuck at minus 34 percent. Analysts see promise and set a 24 dollar target, but the numbers simply are not there yet.
We pass. The ethical screen returns insufficient data because basic financial ratios are missing, and a forward price to earnings ratio of minus 34 times tells us nothing useful when earnings do not exist. Without those foundations we cannot weigh the business against our standards, regardless of the strong buy consensus.
Risk sits in the usual clinical stage traps: trial failures, repeated cash raises and dilution. The 26 percent margin to the 24 dollar fair value looks attractive on paper, yet it rests on hope rather than proven cash flow. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TRVI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-15Markup · changed$17.73+24.8%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 24.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (10 analysts) rates it strong buy, with a mean price target of $24.
2026-07-18Accumulation$14.21+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (10 analysts) rates it strong buy, with a mean price target of $24.
2026-07-03Accumulation$14.21+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$14.21Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
